Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Agilysys Inc (AGYS) vs ARK Genomic Revolution ETF (ARKG) Price & Performance

Agilysys IncTrade
ARK Genomic Revolution ETFTrade

Price performance (Past 24H)

Key statistics

Agilysys Inc vs ARK Genomic Revolution ETF — how do they compare? Agilysys Inc trades at $107.52 (market cap $3.00B), while ARK Genomic Revolution ETF trades at $44.62. The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Agilysys Inc nearer its low. Which is the better fit depends on your goals.

AGYSARKG
Market Cap
$3.00B
Sector
TechnologySector/Thematic
52-Week High
$141.12$44.55
52-Week Low
$62.19$24.02
Enterprise Value
$2.90B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Agilysys Inc

Agilysys (AGYS) trades at $106.14, down 0.79% for the day, with a bullish technical signal from moving averages and a consensus analyst price target of $118.33. Recent Q1 2026 earnings beat expectations with EPS of $0.63 versus $0.4971, and the company raised its full-year outlook, driven by strong subscription revenue growth and deployment progress with key clients like Marriott.

The outlook is positive given robust earnings momentum and 100% buy ratings from analysts, though high valuation multiples (P/E of 70.01) and negative net cash flow in 2025 pose risks. Upside potential exists if subscription-led growth continues, but investors should monitor execution against elevated expectations.

ARK Genomic Revolution ETF

ARKG trades at $44.49, up 0.41% today, with a bullish technical bias from moving averages but overbought RSI signals. The ETF focuses on genomic revolution stocks, with top 10 holdings comprising 59% of assets and a long-term EPS growth rate of 10.7% (Seeking Alpha, 2026-07-28). Recent news highlights biotech sector strength driven by FDA friendliness and AI-driven drug discovery.

Outlook is cautiously optimistic given sector tailwinds, but high concentration and volatility pose risks. The ETF's exposure to small- and mid-cap biotech offers growth potential, yet investors face regulatory and market sentiment shifts. Near-term performance may hinge on broader tech trends and biotech M&A activity.

Returns comparison

Trailing returns across standard periods

About Agilysys Inc

Agilysys provides enterprise software and SaaS solutions for the hospitality industry. Its products specialize in point-of-sale, property management, and inventory systems for hotels, resorts, and cruise lines.

Read more on AGYS

About ARK Genomic Revolution ETF

ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.

Read more on ARKG